Core Insights - Ginkgo Bioworks aims to become a leading biotech partner in the biopharma sector through low-cost bioengineering and biomanufacturing services, but it currently faces significant challenges [1][2] Group 1: Biofoundry and Automation - Ginkgo's biofoundry provides a platform for biotech and pharma companies to design and cultivate microorganisms at scale, generating desired outputs like biomolecules [3] - The company utilizes custom-built laboratory automation hardware, specifically reconfigurable-automation carts (RACs), to create a highly automated and customized workflow [5][6] - The efficiency of RACs compared to traditional high-throughput solutions is a critical factor for the company's operational success [7][8] Group 2: Financial Health - As of the first quarter, Ginkgo had $840 million in cash and cash equivalents, with operating expenses of $215.9 million, leading to a net cash decrease of $102.3 million [9] - The company has initiated a cost-cutting campaign aimed at reducing expenses by approximately $200 million annually, including a 25% reduction in personnel costs [10][11] Group 3: Stock Performance and Delisting Risk - Ginkgo's stock has declined by 42% over the past year, with a current share price of around $0.74, below the $1 minimum bid price required by the New York Stock Exchange [12][13] - The company has been warned about potential delisting and has six months to regain compliance, with options such as a reverse-share split or announcing new initiatives to boost share price [13][14]

Reasons to buy Ginkgo Bioworks The company's cell engineering platform combines robotics and artificial intelligence (AI) to produce new cell lines for its clients. This is important because many top-selling drugs are manufactured by genetically modified cells that produce a specific protein. Disrupting the biopharmaceutical manufacturing industry could be extremely lucrative and it isn't the only way Ginkgo's cell engineering platform can earn money. For example, it recently partnered with plant-biotech co ...

Is Ginkgo stock a sell? Although possessing enough cash to keep it going for about two years at its current burn rate, I'm just not sure this company is going anywhere fast. To me, that makes Ginkgo stock a sell. Ginkgo Bioworks has become a penny stock -- and that's the least of its problems, Massaro is most concerned with management commentary that new "cell programs" -- of which the company expects to add 100 this year -- are no longer a great forecaster of revenue growth, and may give investors a false ...

Can this struggling stock turn things around? Ginkgo Bioworks (DNA -3.98%) is a cell programming company that claims to have large addressable markets (for bioengineered products) in multiple industries in which it can play a key role, and that those are worth trillions of dollars in total. But the problem is it may take more than a decade for those markets to reach that kind of size. Investors could require a lot of patience. While there may be a lot of potential for the business in the long run, investors ...

A few enterprising businesses are marketing themselves differently. As you may have heard, there's a new trend in biotech lingo wherein companies call themselves "TechBio" rather than "biotech" to emphasize their forward-thinking about the role of information technology. Biotechs like Ginkgo Bioworks (DNA 2.63%), Recursion Pharmaceuticals (RXRX 6.01%), and Schrödinger (SDGR 0.30%) could easily be described by the term, and some, like Recursion, even describe themselves that way. But what does this new term ...

BOSTON, May 15, 2024 /PRNewswire/ -- Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, today announced that management will be participating in two investor conferences in May. Further details, webcast links, and a replay of the presentations, fireside chats, and panels, if available, will be posted on the company's investor relations website at investors.ginkgobioworks.com. About Ginkgo Bioworks Ginkgo Bioworks is the leading horizontal platform for c ...

Sojitz intends to use its extensive network to help Ginkgo foster business connections within the Japanese bioeconomy Ena Cratsenburg, Chief Business Officer, Ginkgo: "We're thrilled to join efforts with Sojitz and collaborate on bolstering the Japanese bioeconomy. Sojitz is a well respected trading company that has extensive relationships with many of the major industrial and chemical companies in Japan. We look forward to working with Japanese companies to leverage our synthetic biology platform to accele ...

Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) Q1 2024 Earnings Conference Call May 9, 2024 5:30 PM ET Company Participants Megan LeDuc – Manager-Investor Relations Jason Kelly - Co-Founder & Chief Executive Officer Mark Dmytruk - Chief Financial Officer Conference Call Participants Rahul Sarugaser - Raymond James Matt Sykes - Goldman Sachs Mike Ryskin - Bank of America Steve Mah - TD Cowen Megan LeDuc Good evening, I’m Megan LeDuc, Manager of Investor Relations at Ginkgo Bioworks. I’m joined by Jason Kelly, our ...

Ginkgo Bioworks Holdings, Inc. (DNA) came out with a quarterly loss of $0.08 per share in line with the Zacks Consensus Estimate. This compares to loss of $0.08 per share a year ago. These figures are adjusted for non-recurring items.A quarter ago, it was expected that this company would post a loss of $0.09 per share when it actually produced a loss of $0.09, delivering no surprise.Over the last four quarters, the company has not been able to surpass consensus EPS estimates.Ginkgo Bioworks, which belongs t ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q ______________________________________________ (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _________________ to _________________ Commission File Number: 001-40097 ______________________ ...